Pembina Pipeline Corporation (PBA) offers transportation and midstream services in North America. Its revenue fell 8% in 2016 before gaining 22% in 9M17.
On November 8, Methanex announced that it entered into a 14-year agreement with Painted Pony Energy for natural gas supplies to its Alberta methanol plant.
Vulcan’s dividend yield Vulcan Materials’ (VMC) 100% dividend-per-share growth in 2016 has been followed by 25% growth in 2017. Its dividend yield curve has sloped upward due to growth in its dividend per share and a sharp drop in its stock price growth. Its stock price has risen 1% YTD (year-to-date), compared with 32% in 2016. The company, like the overall […]
Regeneron (REGN) and Sanofi’s (SNY) Dupixent has seen stronger total prescription (or TRx) performance since its launch than Cosentyx, the dermatology biologic drug by Novartis (NVS).
How ONEOK has maintained a 4% yield ONEOK (OKE), the general partner and 41% owner of ONEOK Partners, owns one of the country’s premier natural gas liquid systems. The company’s revenue grew 15% in 2016 after falling 36% in 2015. The growth was driven by its Natural Gas Gathering and Processing, Natural Gas Liquids, and […]
Stanley Black & Decker’s (SWK) PE ratio of 21.1x is pitted against a sector average of 29.3x. The dividend yield of 1.8% is pitted against a sector average of 1.6%.
Sanofi Pasteur Sanofi Pasteur, Sanofi’s (SNY) human vaccine business, reported 26.2% revenue growth at constant exchange rates to 1.0 billion euros in 2Q17. Sanofi Pasteur reported growth across all product franchises during the quarter. Sanofi Pasteur includes polio/pertussis/Hib (haemophilus influenzae type b) vaccines, adult booster vaccines, meningitis vaccines, influenza vaccines, travel and other endemic vaccines, […]
Sanofi Genzyme In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product revenue from the multiple sclerosis, rare disease, oncology, and immunology franchises, reported a sales increase of ~14.6% to 1.7 billion euros. This rise was […]
Analysts expect Novartis’s (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.
Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17.
GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired the meningitis and other vaccines business from Novartis (NVS).
The Novartis acquisition has improved sales for GSK’s Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe.
Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.
Compared to 43% at the end of 2015, Novartis’s (NVS) Entresto managed to attain a preferred formulary position in 66% of commercial plans in the US at the end of 2016.
Novartis’s Innovative Medicines segment, formerly referred to as its Pharmaceuticals segment, consists of products for therapeutic areas including oncology, respiratory, and established medicines.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment fell substantially in 2015 due to its divestment of its oncology business to Novartis (NVS) in March 2015.
Novo Nordisk’s (NVO) diabetes and obesity care portfolio consists of modern insulin, Victoza, human insulin, new generation insulin, and other diabetes and obesity care products.
Nitrogen selling prices PotashCorp (POT) sells nitrogen fertilizers such as ammonia, urea, and nitrogen solutions. It competes with other natural gas–based nitrogen producers such as CF Industries (CF) and Terra Nitrogen (TNH), which primarily produce and sell nitrogen fertilizers. Agrium (AGU), which is a part of the PowerShares International Dividend Achievers ETF (PID), produces nitrogen fertilizers […]
In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments.
With 642 million people expected to suffer from diabetes globally by 2040, the disease is expected to offer multiple growth opportunities for Novo Nordisk.
Teva Pharmaceutical Industries accounts for 18% of the US generic drug market. This share is significantly higher than those of Mylan, Novartis, and Pfizer.
Teva Pharmaceutical Industries plans to take advantage of market dynamics and unmet demand in generic pharmaceuticals by enacting a three-pronged strategy.
With improvements in the supply chain and successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance.
Sanofi is swapping its animal health business with Boehringer Ingelheim’s consumer healthcare business. The asset swap deal was signed on June 27, 2016.
Sanofi’s Consumer Healthcare segment includes Allegra, Doliprane, Nasacort, and other products. It reported a 4.3% decline in revenues to 800 million euros.
After Sanofi’s reorganization, Genzyme now includes products for multiple sclerosis, rare diseases, and oncology. Genzyme’s sales increased ~19.5% in 2Q16.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.
GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.
Sanofi’s (SNY) Cardiovascular franchise includes Praluent and Multaq. Praluent, an injection for lowering LDL cholesterol, was launched in collaboration with Regeneron in July 2015 in the US markets, where it reported sales of 9 million euros in 1Q16.
Agrium (AGU), one of the major agricultural fertilizer retailers, reported its 1Q16 adjusted EPS of $0.02 per share on May 3, 2016. That beat analysts’ estimate of -$0.05 per share.
Novo Nordisk’s US sales rose annually by 12% in local currency in 1Q16. North America remained its major market, constituting ~50% of its total revenue.
